Combination kit used in the treatment of malaria

US7404962B1 · kind B1 · utility

Assignees

• NICHOLAS PIRAMAL INDIA LIMITED
• COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH · IN

Inventors

• Francis Joseph Pinto · Mumbai, IN
• Swati Ajay Piramal · Mumbai, IN
• Ram Pratap · Lucknow, IN
• Amiya Prasad Bhaduri · Lucknow, IN
• Harsh Pati Thapliyal · Lucknow, IN
• Sunil Puri · Burnaby, CA
• Guru Prasad Dutta · Lucknow, IN
• Anil Kumar Dwivedi · Lucknow, IN
• Satyawan Singh · Lucknow, IN
• Pratima Srivastava · Lucknow, IN
• Vikash Chandra Pandey · Lucknow, IN
• Sudhir Srivastava · Eindhoven, NL
• Shio Kumar Singh · Lucknow, IN
• Ram Gupta · Lucknow, IN
• Jagdishwar Sahai Srivastava · Lucknow, IN
• Omkar Prasad Asthana · Lucknow, IN

Key dates

• Filing date: Aug 30, 2000
• Grant date: Jul 29, 2008
• Expiry date: Aug 11, 2022

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A combination kit for the treatment of malaria caused by Plasmodium vivax (P. vivax) having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in the form of capsules; individual doses of the anti-malarial agent, chloroquine in the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), three to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one each to be taken on days two to six.